Ellex Medical Lasers (ASX:ELX) - Executive Chairman, Victor Previn
Executive Chairman, Victor Previn
Source: The Advertiser
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Medical manufacturer Ellex Medical Lasers (ELX) has received ACCC approval to sell Ellex Lasers & Ultrasound to Lumibird Group SA
  • The companies announced the sale in December 2019, but faced an investigation from the Australian Competition and Consumer Commission (ACCC)
  • The ACCC has since approved the transaction, since it will not impact competition in the ophthalmology laser and ultrasound market
  • Lumibird Group and Ellex have agreed to complete the transaction on June 30, 2020
  • Ellex Medical Lasers shares are down 4.07 per cent today, trading for 59 cents each

Medical manufacturer Ellex Medical Lasers (ELX) has received ACCC approval to sell Ellex Lasers & Ultrasound to Lumibird Group SA.

The company first announced the agreement to sell its business to Lumibird on December 24, 2019. At the time, Ellex said that the share sale and purchase agreement was worth approximately $100 million.

The announcement also stated that Lumibird Group would pay cash to acquire all of the company’s laser and ultrasound products. However, this did not include the Ellex 2RT and Ellex iTrack business segments.

Completion of the transaction with Lumibird depended on meeting a number of purchase agreement conditions. In particular, the sale faced an investigation from the Australian Competition and Consumer Commission (ACCC).

Ellex announced the commencement of ACCC’s public review of the acquisition on May 1, 2020. At the time, the commission said that it would provide an indicative decision by June 25, 2020.

The ACCC investigated if the sale could have an impact on competition in Australia’s ophthalmology laser and ultrasound market. During the process, feedback from customers and other industry participants suggested quite the contrary.

The Australian market for such products is fairly small, in comparison to markets which the companies operate in globally. Also, Lumibird has relatively low sales in the ophthalmology laser and ultrasounds categories in Australia.

Based on suggestions that the sale will not impact competition, the ACCC recently came to a decision. In a public press release, the commission stated that it will not oppose the transaction.

Ellex welcomed the ACCC’s decision, which will allow the transaction to finally proceed. The company is also looking forward to the associated returns to shareholders which the transaction will bring. 

Lumibird Group and Ellex have agreed to complete the transaction on June 30, 2020.

Ellex Medical Lasers shares are down 4.07 per cent today, trading for 59 cents each at 1:18 pm AEST.

ELX by the numbers
More From The Market Online

ResMed spikes on robust results and global growth spurt

ResMed shares have climbed following the release of the company's strong Third Quarter FY2024 results.

PharmAust CEO’s sayanora triggers stock plunge

Clinical-stage biotechnology company, PharmAust shares plunged 24 per cent so this morning, following the resignation of…

Recce wins safety board approval to dose 4g in R327 UTI infusion trial

Recce Pharma will dose patients with 4g of its R327 intravenous solution to treat UTIs in…

Emyria locks in $2.3M to progress MDMA research – with Chair adding $0.3M

WA-based and ASX-listed Emyria is seeking to further research using MDMA to treat PTSD. The chair…